The iBio Technology has been validated by major industry players, as well as the Brazilian government, opening iBio’s doorway to the world market.
With extensive patent protection and proprietary know-how, iBio creates a high barrier to entry for competitors.
iBio’s global commercialization program, which was started in the favorable Brazilian market, is also licening the iBio Technology to key U.S. companies.
The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins and has been validated across a wide range of applications in both vaccines and biotherapeutics.
Closing share price